Introduction
Continuous monitoring is transforming healthcare. What began as periodic point-of-care measurements is evolving into a world where wearable and implantable biosensors provide real-time physiological insights around the clock.
Over the past decade, the biosensor industry has progressed from collecting isolated measurements toward generating continuous streams of biological data. At the same time, advances in artificial intelligence are enabling entirely new ways to understand that data, moving beyond simple observation toward meaningful interpretation.
The result is a fundamental shift: healthcare is increasingly becoming about understanding cause and effect rather than simply recording outcomes.
Webinar Recording
Why Continuous Monitoring Matters More Than Ever
When Zimmer & Peacock first began exploring electrochemical diagnostics over a decade ago, point-of-care testing represented a major opportunity. The ability to perform rapid measurements outside traditional laboratory settings was already reshaping diagnostics.
Today, however, wearable biosensors have emerged as an even larger opportunity.
Consider blood glucose monitoring:
A traditional self-monitoring blood glucose (SMBG) test provides a single snapshot of physiology at one moment in time.
A continuous glucose monitor (CGM), by contrast, provides thousands of measurements throughout the day.
The difference is profound.
A person testing four times per day obtains only four individual data points during a period containing more than 86,000 seconds.
Continuous monitoring captures:
- Rising glucose after meals
- Recovery periods
- Overnight trends
- Exercise responses
- Unexpected physiological events
Rather than observing isolated moments, continuous monitoring enables observation of the entire physiological journey.
📌 More data creates a more complete picture of human biology.
The Real Challenge: Understanding Cause and Effect
Collecting continuous biosensor data is only the first step.
The larger challenge is understanding why physiological changes occur.
For example, a glucose increase could result from:
- Food intake
- Exercise
- Stress
- Illness
- Hormonal fluctuations
- Circadian rhythms
The biosensor measures the effect.
What it often does not directly measure is the cause.
This distinction is becoming increasingly important as the industry moves beyond simply displaying data toward generating actionable insights.
Why Context Matters
A glucose trace without context only tells part of the story.
A glucose trace combined with:
- Meal information
- Physical activity data
- Sleep data
- Stress indicators
- Environmental factors
becomes dramatically more valuable.
This concept of combining multiple data streams is often referred to as multimodal sensing.
Multimodal data enables AI systems to connect physiological responses with real-world behaviour.
The future of biosensing is therefore not just continuous measurement.
It is continuous measurement with context.
What AI Can Learn from a Bouncing Ball
One of the most interesting developments in artificial intelligence is the growing emphasis on physical-world understanding.
Researchers such as Yann LeCun have highlighted the limitations of large language models when it comes to understanding real-world cause and effect.
A language model can describe a bouncing ball.
It does not necessarily understand the physics behind the bounce.
Humans do.
A child quickly learns:
- Drop the ball
- Ball falls
- Ball bounces
- Ball can be caught
This understanding of physical causality is fundamental.
The same principle applies to physiology.
While glucose fluctuations are far more complex than a bouncing ball, they also follow cause-and-effect relationships.
The emerging field of Joint Embedding Predictive Architecture (JEPA) seeks to improve AI's understanding of the real world through prediction and contextual learning.
As AI becomes better at understanding physical systems, many of the same principles can be applied to biological systems.
🔬 Physiology may be complicated, but it is still governed by cause and effect.
Continuous Biosensors Need AI, and AI Needs Continuous Biosensors
Continuous glucose monitoring has already demonstrated a critical truth:
People typically make better decisions when they have access to real-time physiological data.
Many studies have shown that individuals who actively engage with their data often achieve improved health outcomes.
The challenge is scalability.
Not everyone wants to analyse graphs and trends daily.
This is where AI becomes essential.
An intelligent system can:
- Monitor patterns continuously
- Identify anomalies
- Link behaviour with outcomes
- Generate personalised recommendations
- Interpret long-term trends
However, AI cannot operate on biosensor data alone.
It requires context.
The future therefore lies in combining:
| Data Type | Examples |
|---|---|
| Biosensor Data | Glucose, lactate, hormones, electrolytes |
| Behavioural Data | Food intake, exercise, sleep |
| Environmental Data | Temperature, location, timing |
| Physiological Signals | Heart rate, HRV, PPG |
Together these data streams create understanding rather than observation.
Industry Leaders Are Moving Toward Multimodal Monitoring
The largest companies in digital health are increasingly converging on this same vision.
Dexcom and Oura
Dexcom has invested in Oura, reflecting growing interest in combining glucose measurements with additional physiological data streams.
Abbott and Whoop
Abbott's investment in Whoop demonstrates the value of integrating continuous biosensing with fitness and recovery metrics.
Apple
Apple has spent years exploring non-invasive glucose monitoring technologies while building one of the world's largest wearable ecosystems.
Samsung
Samsung continues to invest heavily in health monitoring and glucose-related research.
Google and Abbott
Google Health's integration efforts with Abbott's Lingo platform highlight the growing importance of unified health data ecosystems.
💡 The trend is clear: meaningful healthcare insights increasingly come from combining multiple streams of data rather than relying on a single sensor.
Why Single Measurements Can Be Misleading
One practical demonstration highlights an important limitation of traditional point-of-care testing.
A glucose meter measures a single blood sample.
Like any measurement system, it is vulnerable to errors introduced during sampling.
Even something as simple as food residue on a fingertip can dramatically alter a reading.
Continuous systems help overcome this challenge because they rely on trends rather than isolated points.
A single incorrect data point becomes less significant when surrounded by hundreds or thousands of additional measurements.
✅ Continuous monitoring creates resilience against occasional measurement errors.
Screen Printed Electrodes: The Foundation of Modern Biosensors
Despite the sophisticated appearance of modern wearable devices, many originate from a surprisingly familiar manufacturing platform.
Screen printed electrodes (SPEs) remain foundational technology for electrochemical sensing.
In fact, many glucose monitoring technologies share common manufacturing origins with traditional electrochemical test strips.
Applications include:
- Continuous glucose monitors
- Disposable biosensors
- Wearable sensors
- Research platforms
- Implantable sensor development
Researchers and developers exploring new sensing concepts often begin with standard SPE platforms before progressing to custom sensor designs.
For teams engaged in biosensor R&D, Zimmer & Peacock provides a range of commercially available screen printed electrode platforms:
🔗 Screen Printed Electrodes:
https://shop.zimmerpeacock.com/en-gb/collections/bare-electrodes
For early-stage development, off-the-shelf electrodes frequently provide the fastest route to generating experimental data before investing in custom manufacturing.
The Hidden Reality of Biosensor Development
One persistent misconception within the startup ecosystem is that sophisticated biosensor platforms can be developed rapidly with minimal funding.
The reality is often very different.
Developing robust wearable and implantable sensing systems typically requires:
- Thousands of experiments
- Extensive materials optimisation
- Electronics development
- Data analytics infrastructure
- Manufacturing process development
- Regulatory planning
- Clinical validation
The timelines are substantial.
The investment requirements are equally substantial.
Several high-profile continuous monitoring companies have raised tens or hundreds of millions of dollars while spending years advancing toward commercial deployment.
The lesson is not to discourage innovation.
Rather, it is to encourage realistic planning.
⚙️ Successful biosensor programmes are built on disciplined scientific development rather than shortcuts.
Beyond Wearables: The Rise of Implantable Biosensors
Wearable biosensors represent a major advancement, but implantable biosensors may ultimately provide even richer physiological data.
Zimmer & Peacock has spent years developing implantable sensor systems for veterinary and translational research applications.
These systems have been deployed in:
Aquaculture Applications
Implantable glucose sensors have been successfully implanted into fish, enabling real-time physiological monitoring and wireless data transmission.
Large Animal Models
Advanced implantable platforms have also been deployed in pigs, where multiple sensors can operate simultaneously while streaming physiological data to cloud-connected systems.
This work demonstrates the increasing maturity of implantable sensing technologies.
While wearables remain the most practical route for many commercial products, implantables represent the next frontier in continuous monitoring.
From Sensors to Cloud Analytics
Modern biosensor systems no longer stop at the sensor itself.
Complete ecosystems now include:
- Sensor hardware
- Electronics
- Wireless connectivity
- Cloud platforms
- Analytics dashboards
- AI-driven insights
The value increasingly lies in the complete system.
For teams developing connected biosensor solutions, data infrastructure is becoming as important as the sensing chemistry itself.
Zimmer & Peacock's Djuli cloud platform illustrates this trend towards integrated biosensor ecosystems:
🔗 Djuli Cloud Platform:
https://djuli.zimmerpeacock.no/
Practical Takeaways
✅ Continuous monitoring provides significantly greater physiological insight than isolated measurements.
✅ Context matters as much as the biosensor measurement itself.
✅ Future healthcare platforms will increasingly combine biosensors, wearables, behavioural data, and AI.
✅ Multimodal sensing is becoming a strategic priority across the digital health industry.
✅ Screen printed electrodes continue to underpin many cutting-edge biosensor technologies.
✅ Implantable biosensors represent the next major evolution beyond wearable monitoring.
✅ Building successful biosensor platforms requires realistic expectations regarding time, funding, and scientific development.
Looking Ahead
The convergence of biosensors, AI, cloud connectivity, and multimodal health data is creating opportunities that were difficult to imagine even a decade ago.
Wearable biosensors have already changed the way we monitor health. Implantable technologies promise to extend those capabilities even further. At the same time, advances in AI are helping transform physiological signals into meaningful understanding.
The next generation of healthcare technologies will not simply measure biology. They will help explain it.
If you are exploring wearable sensors, implantable biosensors, electrochemical sensing, or connected health platforms, Zimmer & Peacock welcomes discussions with researchers, innovators, and technology developers.
🔗 Contact the team:
https://www.zimmerpeacock.com/contact
#Biosensors #WearableTechnology #ImplantableSensors #Electrochemistry #ScreenPrintedElectrodes #ContinuousMonitoring #DigitalHealth #ArtificialIntelligence
